

Saxenda®

liraglutide injection



Saxenda® is taken just once each day, at any time that is convenient¹



- Patients follow a simple, 4-week dose escalation schedule, designed to minimise potential gastrointestinal side effects¹
- Book follow-up appointments with your Saxenda® patients during the escalation and at week 16 (12 weeks on full dose) to evaluate their progress¹
- Saxenda® should be discontinued if patients have not lost more than 5% of their body weight after 12 weeks on full dose¹

Saxenda® patients may experience nausea. It is usually mild to moderate and transient, and can be minimised with some simple lifestyle advice, including:^{1,2}



TRY TO

- Eat smaller meals
- Stop eating when full
- Drink plenty of water
- Change the time of day Saxenda® is taken



AVOID

- Eating fatty or fried foods
- Eating spicy foods with strong smells
- High-fibre food
- Smoking or drinking alcohol

Encourage your patients on Saxenda® to enrol for access to the coach calls



Your patients with obesity have the Will. You can offer them the Way. Use the only GLP-1 approved by SFDA for chronic weight management.⁶



References

1. Saxenda® [summary of product characteristics].
2. Data on file. Tips that may help you manage common side effects; 2017. Bagsværd, Denmark: Novo Nordisk A/S.
3. Pi-Sunyer X, Astrup A, Fujioka K, et al; for the SCALE Obesity and Prediabetes NN8022-1839 Study Group. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. *N Engl J Med*. 2015;373(1):11-22 and supplementary appendix. doi:10.1056/NEJMoa1411892.
4. le Roux CW, Astrup A, Fujioka K, et al; for the SCALE Obesity and Prediabetes NN8022-1839 Study Group. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. *Lancet*. 2017;389(10077):1399-1409.
5. Internal calculations by Novo Nordisk based on IQVIA™ database: based on Novo Nordisk ex-factory volume sales by month. Each patient assumed to be on 3mg liraglutide per day.
6. SFDA data base of registered drugs available on: <https://www.sfda.gov.sa/en/drug/resources/Pages/DrugsUnderRegistrations.aspx> accessed 1 April 2020

GLP-1 = glucagon-like peptide-1.